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Inhaled medication is the cornerstone of the pharmacological treatment of patients with
asthma and COPD. The major two classes of inhaled medication include corticosteroids (ICS)
and bronchodilators. There is a wide diversity in molecules in both classes. Moreover, there
is a wide variation in delivery systems.
The correct use of inhalers is not granted and patients often incur in many mistakes when
using pMDIs and DPIs, despite repeated instructions. A better matching between patient and
device could be accomplished if the physician is aware of: (1) the patient characteristics (dis-
ease, severity, fluctuation in airflow obstruction, etc); (2) what class of medication is3610325, þ31 6 55102461 (mobile); fax: þ31 24 3610324.
.umcn.nl (P.N.R. Dekhuijzen).
hed by Elsevier Ltd.
3.09.013
Open access under CC BY-NC-ND license.
1818 P.N.R. Dekhuijzen et al.indicated; (3) where in the lung the medication should be delivered; and, (4) how this can be
best achieved by a given device in this specific patient.
We focus on the prescription of pMDIs and DPIs at the GP office or at the outpatient clinic of
the hospital, and we propose an evidence based approach enabling the caregiver to make a
rational choice in only a few minutes by just considering the following four simple questions:
Who?, What? Where? and How? (the so-called 3WeH approach).
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Inhaledmedication is the cornerstone of the pharmacological
treatment of patients with asthma and COPD. The major two
classes of inhaled medication include corticosteroids (ICS)
and bronchodilators. There is a wide diversity in molecules in
both classes. Moreover, there is a wide variation in delivery
systems. The most frequently used are pressurized metered
dose inhalers (pMDIs) and dry powder inhalers (DPIs) [13].
When prescribing a specific inhaler device, clinicians
should consider a number of factors, including the ability to
generate an adequate inspiratory flow, the capacity to
handle the device appropriately and, importantly, its co-
ordination with the inspiratory effort.
However, the correct use of inhalers is not granted and
patients often incur in many mistakes when using them
[6,8,10,15]. Mistakes are made both with pMDIs [14] and
DPIs [12], despite repeated instructions [20]. These in-
structions should be uniform among all caregivers but this is
often not the case. In addition, reduced adherence and
compliance are associated with misuse of inhaler device on
the one hand and have been linked to poor asthma control
[5] and COPD outcomes on the other [7]. This may increase
morbidity and perhaps even mortality. Clearly, this impacts
on the financial costs of treating these patients [9]. These
and other factors are summarized in Table 1 and may
negatively influence the optimal use of inhalers (Table 2).
A better matching between patient and device could be
accomplished if the physician is aware of: (1) the patient
characteristics (disease, severity, fluctuation in airflow
obstruction, etc); (2) what class of medication is indicated;
(3) where in the lung the medication should be delivered;
and, (4) how this can be best achieved by a given device in
this specific patient.
The aim of this paper is to assist the caregiver in pre-
scribing inhaled in prescribing themost appropiate inhaler for
adult patients by using a evidence-based rational andeffective approach.We focus on the prescription of pMDIs and
DPIs at theGPoffice or at the outpatient clinic of the hospital,
and we propose an evidence based approach enabling the
caregiver to make a rational choice in only a few minutes by
just considering the following four simple questions: Who?,
What? Where? and How? (the so-called 3WeH approach).
Who? consider asthma and COPD disease
characteristics
Firstly, it is important to determine if a patient has asthma
or COPD (or an overlap syndrome). In some cases, the
diagnosis might have been already established but sugges-
tive features of COPD and asthma are listed in Table 1 [17].
Both in asthma and COPD there is a wide spectrum of
severity, with wide variations in levels of airflow limitation,
level of hyperinflation at rest and during exercise, and the
work of breathing in stable and unstable disease. It is
important to consider these aspects because they may
eventually influence the choice of a specific device. Ideally,
the device should be suitable for a specific patient in stable
and unstable clinical conditions. An important determinant
is his/her ability to generate adequate inspiratory flow,
especially in the case of a DPI. In patients with severe hy-
perinflation (as it occurs in some patients with COPD and
during asthma attacks) inspiratory flow rate may be
reduced. In addition, inspiratory muscles may be at me-
chanical disadvantage in the presence of severe hyperin-
flation. This may contribute to the sense of dyspnoea during
inhalation via a DPI and may thus reduce efficacy. Other
issues to consider include the presence of comorbidities
(e.g. arthritis) which may affect inhaler handling.
What? consider the type of drug to use
Inhaled corticosteroids (ICS) are the cornerstone of anti-
inflammatory treatment in patients with asthma. Several
Table 1 Important factors to consider when selecting an inhaler device for a specific patient.
Patient-related factors Including (i) the ability to inhale consciously, handle the device
and coordinate the use of the device and the inspiratory effort,
(ii) patient’s preference and (iii) adherence and compliance. Other factors
may include age and comorbidities.
Disease-related factors Since (i) severe and/or acute airflow obstruction may compromise the ability
to generate an adequate inspiratory flow and (ii) therapeutic strategy and
indications not the same for asthma and COPD.
Device-related factors As the optimal inhalation profile differs between pMDIs (slow inspiration is
preferable) and DPIs (high-flow inhalation in required, with fast acceleration
especially for reservoir devices).
Caregivers-related factors Accounting for the availability and knowledge of professionals involved in
information and education (general practitioners, specialists, nurses,
physiotherapists, pharmacists).
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local potency, oropharyngeal side effects, and particle size
(see below). In patients with more than mild asthma, the
combination of an ICS and a LABA in one inhaler is often
prescribed.
In COPD, the primary pharmacologic intervention con-
sists of long-acting inhaled bronchodilators. The response
of patients to inhaled anticholinergics, beta agonists and
the combination of these two may vary. Lung function
response is a poor predictor of clinical response, which has
to be prioritized. The initial and subsequent choices may
also be influenced by the existing comorbidity and potential
side effects of inhaled bronchodilators. For example, b2
agonists should be avoided in patients with tremor. Anti-
cholinergics should be avoided in case of glaucoma and a
history of urinary retention. A debate is still going on what
to choose for patients with high risk of rythmic and/or
ischaemic cardio-vascular side-effects, since both anti-
cholinergics and b2 agonists may lead to such effects.Where? targeting the medication
Bronchial asthma is characterized by an eosinophilic in-
flammatory process in the airways, which is presentTable 2 Suggestive features for differential diagnosis of COPD
Table 1. Suggestive features for differential diagnosis of COPD an
COPD
Onset Mid-life (rare before age 35)
Symptoms Typically dyspnoea, cough, mucus production
Slowly progressive
Dyspnoea during exercise
Smoking history Long history of tobacco smoking
likely (current or ex-smoker)
Co-morbidities Chronic diseases common, e.g. heart disease
osteoporosis, diabetes, depression
Family history History of obstructive airway
disease increases risk
Airflow obstruction Not completely reversiblethroughout all airways, both the large airways and the
small peripheral airways with a diameter of 2 mm and less.
These small airways comprise most of the airway surface
in the lungs. In addition, this inflammatory process ex-
tends even to the alveolar compartment. This so-called
peripheral inflammation may be related to the clinical
manifestation of the severity of asthma. The periphery of
the lung contains a very high concentration of steroid re-
ceptors [1]. Targeting the small airways with ICS with a
small particle size and a high peripheral deposition may
result in better control of the disease in a subset of pa-
tients. Indeed, several clinical-mechanistic studies have
shown that, in contrast to the ‘conventional’ ICS with
‘large’ particles, these ultrafine ICS may induce functional
and immunologic alterations in the peripheral lung
compartment [18].
The pathology in COPD is characterized by inflammation,
mucus hypersecretion, oedema, bronchospasm and in case
of emphysema, loss of alveolar retraction forces. All these
changes reduce the patency of the small airways. Maximal
bronchodilatation (e.g. bronchiolodilatation) thus reduce
air trapping at rest and during exercise [11]. b-2 receptors
are present everywhere in the lung, with the highest con-
centration in the periphery of the lung [2]. Cholinergic re-
ceptors are also present everywhere in the airway walls,and asthma from [17].
d asthma [1,12].
Asthma
Early life, usually childhood
Typically dyspnoea, cough, chest tightness,
wheeze (often occurring at night or early morning)
Vary from day to day (can improve with removal of triggers)
Dyspnoea after exercise
Possible
, Allergy, rhinitis and/or eczema often present
Family history of asthma or allergy
increases risk 2e6-fold
In most instances completely reversible
Figure 1 Choosing an inhalator: decision tree in adults with COPD and asthma from [4].
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proximal airways [3].How? matching patient, molecule, dose and
device
We propose that the choice for a particular inhaler device
in a given patient should follow the algorithm shown in
Fig. 1. The first step addresses the issue of whether the
patient can inhale medication consciously. Elderly patients
with cognitive limitations are limited in these abilities. The
second step addresses the issue of whether the patient can
generate a minimal inspiratory flow. Patients with COPD
and severe hyperinflation and asthma patients during ex-
acerbations may have reduced ability to generate an
adequate inspiratory flow rate through DPIs, especially
those with a high internal resistance [19]. Finally, the third
step concerns adequate hand-lung coordination. According
to this algorithm, Fig. 1 proposes different options (Blocks A
to E) to be considered in different patient types.
Block A refers to patients with adequate inspiratory flow
rate and good coordination. Any available DPI and pMDI can
be prescribed. In case of oropharyngeal complaints a pMDI
with a low oropharyngeal deposition or a traditional pMDI
combined with a spacer should be considered.
Block B relates to patients with sufficient inspiratory
flow but poor hand-lung coordination. A traditional pMDI is
not sufficient in this case. Options now include a new pMDI
with a low oropharyngeal deposition, a breath-actuated
pMDI, and a pMDI with spacer.
Block C includes patients with insufficient inspiratory
flow but adequate coordination. Examples are severe COPD
patients and patients with severe asthma and recurrent
exacerbations. Options now include a usual pMDI, a breath-
actuated pMDI and a pMDI with a spacer.Block D refers to patients with insufficient inspiratory
flow and insufficient coordination. Options now include a
breath-actuated pMDI and a pMDI with a spacer.
Finally, Block E relates to patients who are not able to
inhale medication consciously. A pMDI with spacer or a
nebulizer should be considered in this situation.
In addition it is important to try to avoid mixing devices
(e.g. pMDI and DPI) in the same patient. It is difficult to
remember technique for both and there is evidence that
mixed devices are associated with worse disease control in
asthma [16].
Conclusion
An optimal match between patient and device may be
achieved by applying a simple four-model (3 WeH) question
(Who-What-Where-How) approach. We recognize that this
is an empirical proposal that needs prospective experi-
mental validation but we hope that, in the meantime,
physicians around the globe may find it helpful to make the
best inhaler device choice for patients with chronic airway
disease.
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